Methods for the treatment of diabetes-associated dyslipdemia

Details Methods for the treatment of diabetes-associated dyslipdemia Methods for the treatment of diabetes-associated dyslipdemia

2011-08-30

2011-08-30

Weddington, Kevin E (Department: 1629)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S035000, C514S226500, C514S275000, C514S315000, C514S422000, C514S563000, C514S635000, C514S866000

Reexamination Certificate

active

08008328

ABSTRACT:
Methods for the treatment of insulin resistance, diabetes, and/or diabetes associated dyslipidemia by administering niacin and meloxicam are disclosed.

REFERENCES:
patent: 4233299 (1980-11-01), Trummlitz et al.
patent: 6469035 (2002-10-01), Cefali
patent: 2006/0069161 (2006-03-01), Lee et al.
patent: 2005002542 (2005-01-01), None
patent: WO 2007041499 (2007-04-01), None
Patent Cooperation Treaty, PCT International Search Report, mailing date Mar. 27, 2008, completion date Feb. 22, 2008, International Application No. PCT/US07/26456.
Tenenbaum, A. et al., “Atherogenic Dyslipidemia in Metabolic Syndrome and Type 2 Diabetes: Therapeutic Options beyond Statins” (2006) Cardiovascular Diabetology, vol. 5: No. 20; Sep. 26, 2006.
Chen, K. et al., “Antagonism of the Prostaglandin D2 Receptor 1 Suppresses Nicontinic Acid-Induced Vasodilation in Mice and Humans” PNAS. Apr. 25, 2006, vol. 103, No. 17, pp. 6682-6687.
WO 2004/010992 A1 (Desai et al.) Feb. 5, 2004.
American Heart Association, Circulation, Journal of the American Heart Association, NCEP Report, “Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines”, Scott M. Grundy, et al., Circulation. 2004:110:227-239 DOI: 10.1161/01.CIR:0000133317.49796.OE and Correction p. 763. Downloaded from circ.ahajournals.org by on Feb. 26, 2009.
A. M. Pereira Arias, et al., “Indomethacin Does Not Affect Endogenous Glucose Production in Type 2 Diabetes Mellitus”, Horm. Metab. Res. 2001:33:659-663.
Alberto M. Pereira Arias, et al., “Indomethacin Decreases Insulin Secretion in Patients With Type 2 Diabetes Mellitus”, Metabolism, vol. 49, No. 7 (Jul. 2000), : pp. 839-849.
Evelien Dekker, et al., “Indomethacin Stimulates Glucose Production in Adults With UncomplicatedFalciparum malaria”, Metabolism, vol. 47, No. 2 (Feb. 1998), : pp. 217-222.
Hyo-Kyung Han, et al., Research paper: “Improved absorption of meloxicam via salt formation with ethanolamines”, ScienceDiet, European Journal of Pharmaceutics and Biopharmaceutics 65 (2007) pp. 99-103.
Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, PA, 1985, p. 1418.
Gennaro, A. R., Remington: The Science and Practice of Pharmacy, 20th Edition, (Lippincott, Williams and Wilkins), 2000.
Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Eaton, Pennsylvania, 1975.
Liberman, et al., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980.
Kibbe, et al., Eds., Handbook of Pharmaceutical Excipients (3rd Ed.), American Pharmaceutical Association, Washington, 1999.
Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition (1996), Appendix II, pp. 1707-1711.
PCT International Preliminary Report on Patentability, date of issuance Jul. 28, 2009, mailed Aug. 6, 2009, The International Bureau of WIPO, International Application No. PCT/US2007/026456, International Filing Date Dec. 28, 2007, Applicant Reddy US Therapeutics, Inc., et al.
European Communication pursuant to Rules 161 and 162 EPC, dated Sep. 9, 2009, European Patent Office, 2280 HV Rijswijk Netherlands, European Patent Application No. 07863294.0—1216 PCT/US2007026456, Applicant Reddy US Therapeutics, Inc.
Reply to the communication under Rule 161 and 162 EPC with new claims 1 to 15 to replace the claims previously on file, filed Sep. 24, 2009, in response to outstanding European Communication pursuant to Rules 161 and 162 EPC, dated Sep. 9, 2009, European Patent Office, 2280 HV Rijswijk Netherlands, European Patent Application No. 07863294.0—1216 PCT/US2007026456, Applicant Reddy US Therapeutics, Inc.
Communication Pursuant to Article 94(3) EPC, European Patent Office, dated Jul. 27, 2010, European Patent Application No. 07863294.0—2123 / 2120959, Applicant Dr. Reddy's Laboratories Ltd.
Communication with extended European search report, European Patent Office, dated Apr. 22, 2010, completed Mar. 19, 2010,European Patent Application No. 07863294.0—2123 / 2120959 PCT/US2007026456, Applicant Dr. Reddy's Laboratories Ltd.
Gonzalez-Ortiz M et al: “Inhibition of cyclooxygenase-1 or 2 on insulin sensitivity in healthy subjects” Horomone and Metabolic Research, vol. 33, No. 4, Apr. 2001, pp. 250-253, XP009131156.
Helmersson Johanna et al: “Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population” Circulation, Lippincot Williams and Wilkins, Baltimore, US, vol. 109, No. 14, Apr. 13, 2004, pp. 1729-1734, XP002488915.
Schmidt Maria Ines et al: “Diabesity: An inflammatory metabolic condition.” Clinical Chemistry and Laboratory Medicine, vol. 41, No. 9, Sep. 2003, pp. 1120-1130, XP009131179.
Jungnickel P W et al: “Effect of two aspirin pretreatment regimens on niacin-induced catuneous reactions” Journal of General Internal Medicine, Philadelphia, PA, US, vol. 12, No. 10, Jan. 1, 1997, pp. 591-596, XP002956938.

Affiliated with

Also associated with

Rating

Methods for the treatment of diabetes-associated dyslipdemia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for the treatment of diabetes-associated dyslipdemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of diabetes-associated dyslipdemia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2709207